^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunostimulant

    Related drugs:
    1d
    A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, Emergent BioSolutions | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    1d
    Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax (clinicaltrials.gov)
    P=N/A, N=10, Not yet recruiting, Emergent BioSolutions | Trial completion date: Jul 2026 --> Aug 2027 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    1d
    Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) (clinicaltrials.gov)
    P2, N=105, Active, not recruiting, Fondazione Ricerca Traslazionale | Recruiting --> Active, not recruiting | Trial completion date: May 2025 --> Sep 2028 | Trial primary completion date: Oct 2023 --> Sep 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • docetaxel • Tedopi (OSE 2101)
    1d
    Neoadjuvant endocrine treatment plus mammaglobin-A DNA vaccine induces antitumor immune responses in the primary tumor and peripheral blood of breast cancer patients: Insights from a phase 1b clinical trial. (PubMed, Cancer Immunol Res)
    In addition, post-vaccination tumor samples exhibited close spatial interactions between cytotoxic CD8+ T cells (CTL) and Mam-A+ tumor cells and between CTL and antigen-experienced CD4+ T cells. Together, these results suggest that Mam-A DNA vaccination elicits both systemic and intratumoral antitumor immune responses.
    P1 data • Journal
    |
    ER (Estrogen receptor) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • SCGB2A2 (Secretoglobin Family 2A Member 2)
    |
    ER positive
    |
    mammaglobin-A DNA vaccine
    1d
    A Minimal Model Framework for Robust CAR-T Cell and Oncolytic Virus Combination Therapy. (PubMed, Res Sq)
    We develop mathematical models to analyze IL-13R$alpha$2-targeting CAR-T cells and the oncolytic virus C134 using patient-derived glioblastoma data...Models with and without CAR-T exhaustion produce identical fits, indicating that exhaustion dynamics do not improve predictions within the 72-hour observation window. Overall, our results demonstrate that simplified QSS formulations effectively capture viral dynamics and provide a practical framework for optimizing combination immunotherapies.
    Journal
    |
    IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2)
    2d
    NOVA-HIV: A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV (clinicaltrials.gov)
    P4, N=275, Recruiting, University of British Columbia | N=450 --> 275
    Enrollment change
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    2d
    A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults (clinicaltrials.gov)
    P1/2, N=991, Completed, GlaxoSmithKline | Recruiting --> Completed | Trial primary completion date: Aug 2025 --> Jan 2026
    Trial completion • Trial primary completion date
    2d
    Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients (clinicaltrials.gov)
    P2, N=56, Not yet recruiting, Fred Hutchinson Cancer Center
    New P2 trial
    2d
    Shingrix In Recipients of Allogeneic Transplants (clinicaltrials.gov)
    P2, N=55, Recruiting, University of Colorado, Denver | Trial primary completion date: Dec 2025 --> Jan 2028
    Trial primary completion date
    2d
    A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers (clinicaltrials.gov)
    P2, N=360, Active, not recruiting, ModernaTX, Inc. | Trial completion date: Feb 2026 --> May 2026 | Trial primary completion date: Feb 2026 --> May 2026
    Trial completion date • Trial primary completion date
    3d
    A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar (clinicaltrials.gov)
    P1, N=120, Completed, International Vaccine Institute | Active, not recruiting --> Completed
    Trial completion
    3d
    SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER (clinicaltrials.gov)
    P=N/A, N=1100, Active, not recruiting, Pfizer | Trial completion date: Feb 2029 --> Oct 2027 | Trial primary completion date: Feb 2029 --> Oct 2027
    Trial completion date • Trial primary completion date